Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas

References

• Eroglu Z, Zaretsky JM, Hu-Lieskovan S, et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018;553(7688):347–10. doi:10.1038/nature25187.
   PubMed Web of Science ®Google Scholar
• Ochoa CE, Joseph RW. Desmoplastic melanoma: a brief review and the efficacy of immunotherapy. Expert Rev Anticancer Ther. 2019;19(3):205–207. doi:10.1080/14737140.2019.1574573.
   PubMed Web of Science ®Google Scholar
• Stowman AM, Hickman AW, Mauldin IS, Mahmutovic A, Gru AA, Slingluff CL. Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res. 2018;28(3):237–245. doi:10.1097/CMR.0000000000000439.
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35(11):571–580. doi:10.1016/j.it.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Rodriguez AB, Peske JD, Woods AN, Leick KM, Mauldin IS, Meneveau MO, Young SJ, Lindsay RS, Melssen MM, Cyranowski S, et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 2021;36(3):109422. doi:10.1016/j.celrep.2021.109422.
   PubMed Web of Science ®Google Scholar
• Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Kusser K, Randall TD. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci. 2007;104(25):10577–10582. doi:10.1073/pnas.0700591104.
   PubMed Web of Science ®Google Scholar
• Fleige H, Ravens S, Moschovakis GL, Bölter J, Willenzon S, Sutter G, Häussler S, Kalinke U, Prinz I, Förster R, et al. IL-17–induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med. 2014;211(4):643–651. doi:10.1084/jem.20131737.
   PubMed Web of Science ®Google Scholar
• Barone F, Nayar S, Campos J, Cloake T, Withers DR, Toellner K-M, Zhang Y, Fouser L, Fisher B, Bowman S, et al. IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc Natl Acad Sci. 2015;112(35):11024–11029. doi:10.1073/pnas.1503315112.
   PubMed Web of Science ®Google Scholar
• Domblides C, Rochefort J, Riffard C, Panouillot M, Lescaille G, Teillaud J-L, Mateo V, Dieu-Nosjean M-C. Tumor-associated tertiary lymphoid structures: from basic and clinical knowledge to therapeutic manipulation. Front Immunol. 2021;12:698604. doi:10.3389/fimmu.2021.698604.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–555. doi:10.1038/s41586-019-1922-8.
   PubMed Web of Science ®Google Scholar
• Lynch KT, Young SJ, Meneveau MO, Wages NA, Engelhard VH, Slingluff Jr CL, Mauldin IS. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. J Immunother Cancer. 2021;9(6):e002273. doi:10.1136/jitc-2020-002273.
   PubMed Web of Science ®Google Scholar
• Goc J, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology. 2013;2(12):e26836. doi:10.4161/onci.26836.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual: melanoma Staging: AJCC 8 th Edition. CA Cancer J Clin. 2017;67(6):472–492. doi:10.3322/caac.21409.
   PubMed Web of Science ®Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–675. doi:10.1038/nmeth.2089.
   PubMed Web of Science ®Google Scholar
• Shain AH, Garrido M, Botton T, Talevich E, Yeh I, Sanborn JZ, Chung J, Wang NJ, Kakavand H, Mann GJ, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet. 2015;47(10):1194–1199. doi:10.1038/ng.3382.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269). doi:10.1126/scisignal.2004088
   Web of Science ®Google Scholar
• Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 2015;112(11):1782–1790. doi:10.1038/bjc.2015.145.
   PubMed Web of Science ®Google Scholar
• Chen C, Gao FH. Th17 cells paradoxical roles in melanoma and potential application in immunotherapy. Front Immunol. 2019;10:187. doi:10.3389/fimmu.2019.00187.
   PubMed Web of Science ®Google Scholar
• Werner F, Wagner C, Simon M, Glatz K, Mertz KD, Läubli H, Griss J, Wagner SN. A standardized analysis of tertiary lymphoid structures in human melanoma: disease progression- and tumor site-associated changes with germinal center alteration. Front Immunol. 2021;12:675146. doi:10.3389/fimmu.2021.675146.
   PubMed Web of Science ®Google Scholar
• Cipponi A, Mercier M, Seremet T, Baurain J-F, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N, et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 2012;72(16):3997–4007. doi:10.1158/0008-5472.CAN-12-1377.
   PubMed Web of Science ®Google Scholar
• Busam KJ, Mujumdar U, Hummer AJ, Nobrega J, Hawkins WG, Coit DG, Brady MS. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol. 2004;28(11):1518–1525. doi:10.1097/01.pas.0000141391.91677.a4.
   PubMed Web of Science ®Google Scholar
• Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–565. doi:10.1038/s41586-019-1914-8.
   PubMed Web of Science ®Google Scholar
• Kendra KL, Moon J, Eroglu Z, Hu-Lieskovan S, Carson WE, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom JR, et al. Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512). J Clin Oncol. 2022;40(16_suppl):9502. doi:10.1200/JCO.2022.40.16_suppl.9502.
   Web of Science ®Google Scholar